Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia

Oncotarget
Guopan YuDan Xu

Abstract

The treatment of Ph-positive acute lymphoblastic leukemia (Ph+ ALL) has entranced tyrosine kinase inhibitors (TKIs) era. Currently both imatinib and dasatinib are registered as the front-line treatment for Ph+ ALL, and the other 2nd-generation TKIs are suggested as an alternative for those who failed the first-line treatment. However, it remains unclear who could benefit from the 2nd-generation TKIs as the first-line treatment for Ph+ ALL. In this study we compared the efficacy and safety of the 1st and 2nd-generation TKIs in the front-line treatment of Ph+ ALL and found a trend toward better disease-free survival (DFS) in the 2nd-generation TKIs group, though no significant difference in early response and long-term survival between the two groups. Furthermore, subgroup analysis showed that if allogeneic hematopoietic stem cell transplantation (allo-HSCT) was incorporated as consolidation, the 2nd-generation TKIs benefited patients with better DFS and overall survival (OS). The two generation TKIs were well tolerated. Higher incidence of acquiring T315I mutation was observed in the patients relapsed on the 2nd-generation TKIs. These findings suggested front-line treatment of Ph+ ALL with the 2nd-generation TKIs might benefit p...Continue Reading

References

Dec 6, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rajyalakshmi LuthraL Jeffrey Medeiros
Apr 18, 2006·Seminars in Hematology·Richard A Larson
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Feng R LuoFrancis Y Lee
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Simona SoveriniUNKNOWN GIMEMA Working Party on Chronic Myeloid Leukemia
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil P ShahAndreas Hochhaus
Apr 9, 2010·Current Opinion in Pulmonary Medicine·Anupama G Brixey, Richard W Light
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanAlessandro Rambaldi
Aug 15, 2013·Journal of Cancer Research and Clinical Oncology·Andreas Hochhaus, Hagop Kantarjian
Apr 17, 2015·Blood·Yves ChalandonUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Feb 20, 2016·Annals of Hematology·Michele MalagolaMichele Baccarani

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.